Biosynth expands Berlin site
Staad/Berlin - Biosynth has expanded its location in Berlin. The company, which specializes in the development of critical raw materials and provides life sciences and diagnostics services, will operate an extended GMP-compliant bioconjugation production plant at the site.
(CONNECT) Biosynth, a developer of critical raw materials and supplier of life sciences and diagnostics services based in Staad in the canton of St.Gallen, has announced in a press release the opening of an extended GMP-compliant bioconjugation production plant at its Berlin location. GMP compliance means adherence to Good Manufacturing Practice and compliance with the mandated safety standards. In this way, Biosynth is increasing its production capacities in the areas of conjugate vaccines and drugs, activated PEGs, and polymer-based drug excipients.
The plant will reportedly facilitate the provision of scalable, diverse, high-quality conjugation services, according to Thomas Eisele, Chief Operations Officer at Biosynth. Frank Leenders, Manager of the Berlin site, adds that the refurbishment of the company’s existing facility “enhances our GMP manufacturing capabilities, reinforcing our commitment to meeting the evolving needs of our customers”.
“Being able to support projects fully, from initial bioconjugate process development to commercial GMP supply, enables us to provide specialized conjugation solutions for diagnostics and therapeutics – strengthening our position as a trusted partner in the Life Science industry”, as Marie Leblanc, Executive Vice President Life Sciences at Biosynth, also explains in the press release. ce/ja